Abstract
Background
Henoch–Schönlein purpura (HSP) can progress to Henoch–Schönlein purpura nephritis (HSPN), and the most effective management remains unclear. Our aim was to evaluate the efficacy of mycophenolate mofetil (MMF) for treating pediatric patients with HSPN and nephrotic-range proteinuria.
Methods
Twelve children, seven boys and five girls, mean age 8.33 (range 6–12) years at the time of HSPN diagnosis with nephrotic-range proteinuria, were treated with MMF. All patients failed steroid treatment, and mean proteinuria at the time of MMF initiation was 5.6 g/d. MMF dosage ranged from 20 to 25 mg/kg per day. Patients also received an angiotensin-converting enzyme inhibitor (cliazapril) at MMF initiation. Mean follow-up was 3.9 (range 2.3–5.5) years.
Results
All patients responded to MMF at a mean of 2.5 (range 1–4 months). Among the 12 patients, MMF was administered for 10 months in five, 12 months in six, and 15 months in one. At last follow-up, all patients had negative proteinuria and normal renal function, and no relapses were noted. No serious adverse effects of MMF were noted in any patient.
Conclusion
MMF is useful for treating pediatric patients with HSPN and nephrotic-range proteinuria.
Similar content being viewed by others
References
Lau KK, Suzuki H, Novak J, Wyatt RJ (2010) Pathogenesis of Henoch-Schönlein purpura nephritis. Pediatr Nephrol 25:19–26
Ronkainen J, Ala-Houhala M, Huttunen NP, Jahnukainen T, Koskimies O, Ormälä T, Nuutinen M (2003) Outcome of Henoch-Schönlein nephritis with nephrotic-range proteinuria. Clin Nephrol 60:80–84
Shenoy M, Bradbury MG, Lewis MA, Webb NJ (2007) Outcome of Henoch-Schönlein purpura nephritis treated with long-term immunosuppression. Pediatr Nephrol 22:1717–1722
Coppo R, Andrulli S, Amore A, Gianoglio B, Conti G, Peruzzi L, Locatelli F, Cagnoli L (2006) Prediction of outcome in Henoch-Schönlein Nephritis in children and adults. Am J Kidney Dis 47:993–1003
Zaffanello M, Brugnara M, Franchini M (2007) Therapy for children with Henoch-Schönlein purpura nephritis: a systematic review. Sci World J 7:20–30
Ronkainen J, Autio-Harmainen H, Nuutinen M (2003) Cyclosporin A for the treatment of severe Henoch-Schönlein glomerulonephritis. Pediatr Nephrol 18:1138–1142
Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Jeong HJ (2005) Henoch-Schönlein purpura nephritis with nephrotic-range proteinuria: histological regression possibly associated with cyclosporine A and steroid treatment. Scand J Rheumatol 34:392–395
Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Kim PK, Jeong HJ (2005) Can azathioprine and steroids alter the progression of severe Henoch-Schönlein nephritis in children? Pediatr Nephrol 20:1087–1092
Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB (2001) Treatment of Henoch-Schönlein Purpura glomerulonephritis in children with high-dose cooticosteroids plus oral cyclophosphamide. Am J Nephrol 21:128–133
Kalliakmani P, Benou E, Goumenos DS (2011) Cyclosporin A in adult patients with Henoch-Schönlein purpura nephritis and nephrotic syndrome; 5 case reports. Clin Nephrol 75:380–383
Park JM, Won SC, Shin JI, Yim H, Pai KS (2011) Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol 26:411–417
Allison AC (2005) Mechanisms of action of mycophenolate mofetil. Lupus 14(Suppl 1):S2–S8
Flores-Suarez LF (2006) Remission of severe relapsing or persistent lupus nephritis using mycophenolate mofeil. Arch Med Res 37:68–72
Lenz O, Fornoni A, Contreras G (2005) Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis. Drugs 65:2429–2436
Bagga A, Hari P, Moudgil A, Jordan SC (2003) Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 42:1114–1120
Spetie DN, Tang Y, Rovin BH, Nadasdy G, Pesavento TE, Hebert LA (2004) Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 66:2411–2415
Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, Ho YW, Lai KN (2005) Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 68:802–812
Borba EF, Guedes LK, Christmann RB, Figueiredo CP, Goncalves CR, Bonfa E (2006) Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int 26:1078–1083
Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YF (2004) Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 65:1842–1849
Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, Hejazi S, Noroozi M, Macooie AA, Gholizadeh A, Gholizadeh L (2010) Treatment of complicated henoch-schönlein purpura with mycophenolate mofetil: a retrospective case series report. Int J Rheumatol 2010:254316
Muzaffar M, Taj A, Sethi N, Kaw D (2010) Rapidly progressing glomerulonephritis secondary to henoch-Schönlein purpura treated with mycophenolate mofetil: a case report with atypical etiology and presentation. Am J Ther 17:e163–e166
Dede F, Onec B, Ayli D, Gonul II, Onec K (2008) Mycophenolate mofetil treatment of crescentic Henoch-Schönlein nephritis with IgA depositions. Scand J Urol Nephrol 42:178–180
Counahan R, Winterborn MH, White RHR, Heaton JM, Meadow SR, Bluett NH, Cameron JS, Chantler C (1977) Prognosis of Henoch-Schönlein nephritis in children. BMJ 2:11–14
Sugiyama H, Watanabe N, Onoda T, Kikumoto Y, Yamamoto M, Maeta M, Ohara N, Maeshima Y, Yamasaki Y, Makino H (2004) Successful treatment of progressive Henoch-Schönlein purpura nephritis with tonsillectomy and steroid pulse therapy. Intern Med 44:611–615
Tanaka H, Suzuki K, Nakahata T, Ito E, Waga S (2003) Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis. Pediatr Nephrol 18:347–350
Deng F, Lu L, Zhang Q, Hu B, Xia X (2011) Improved Outcome of Henoch-Schönlein purpura nephritis by early intensive treatment. Indian J Pediatr. doi:10.1007/s12098-011-0519-5
Wakaki H, Ishikura K, Hataya H, Hamasaki Y, Sakai T, Yata N, Kaneko T, Honda M (2011) Henoch-Schönlein purpura nephritis with nephrotic state in children: predictors of poor outcomes. Pediatr Nephrol 26:921–925
Maschio G, Alberti D, Janin G, Locatelli F, Mann J, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939–945
Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn K-H (1999) ACE inhibitor versus β-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 33:862–868
Fulton B, Markham A (1996) Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51:278–298
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Du, Y., Hou, L., Zhao, C. et al. Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil. Pediatr Nephrol 27, 765–771 (2012). https://doi.org/10.1007/s00467-011-2057-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-011-2057-9